Topic Listing for Affymax

Ability Net Operating Loss Carryforwards Tax Credit Offset Acceptance
Acceptance Application Agreement Applicable Law Accompanying Notes Integral Part Condensed Financial Statements
Account Agreement Account Ownership
Accredited Investor Accretion Redeemable Convertible Preferred Stock Redemption Value
Accrued Liabilities Action Without Meeting
Actions 2006 Actions 2007
Actions 2008 Actions 2009
Actions Pending Addendum Credit Line Account Application Agreement
Addition 184 Additional Address Information
Additional Representation Takeda Additional Representations Warranties Covenants Affymax
Additional Restrictions Adeptide-non-injectable Peptide-based Esa
Adjournment Notice Adjourned Meetings Administration Board
Administration Non-discretionary Grant Program Adoption Sfas 123
Adverse Event Reporting Safety Data Exchange Affidavit Mailing
Affiliate Affymax
Affymax Designation Description Affymax House Marks
Affymax Inc Affymax Inc 4001 Miranda Avenue Palo Alto 94304
Affymax Inc Table Contents Affymax Know-how
Affymax Patent Affymax Patents
Affymax Patents Other Joint Aggregation Stock
Ali Mahdavi Alliance Representative
Allocation Costs Finished Product Allocation Proceeds
Alternate Mailing Address Checks Alternative Esa
Amendment Amendment 111
Amendment 112 Amendment 124
Amendment 411 Amendment Sections
Amendment Waiver Amendments
Amendments Articles Incorporation Bylaws Change Anemia Associated Cancer
Anemia Associated Chronic Kidney Disease Anemia Associated Other Conditions
Anemia Background Anemia Cancer
Anemia Chronic Renal Failure Crf Angiotide-anti-angiogenesis Factor
Anne-marie Duliege Anne-marie Duliege Chief Medical Officer
Annual Awards Annual Meetings
Arising Between Parties Arlene Morris
Arlene Morris President Chief Executive Officer Arrangements Multiple Deliverables
Assessment Assignment
Assignment Form Attorneys Fees
Audit Audit Affymax
Audit Committee Audit Procedures
Audit Product Manufacturer Audit Takeda
Authority Binding Agreement Authorization
Authorized Disclosure Authorized Signatory Borrower Persons Designated Applicable Ubs Bank
Authorized Signatures Completed Vote Counted Date Sign Below Availability Shares
Available Information Available Stock Awards
Aviso Para Fiador Spanish Translation Required Law Backup Compound
Backup Compounds Backup Product
Backup Research Agreement Basis Presentation
Bbb Beneficial Owner Shares Registered Name Broker Bank
Beneficial Ownership Reporting Compliance Beneficiary Designation
Benefit Income Taxes Best After-tax
Blocked Currency Board Directors Recommends Vote Favor Proposal
Borrower Borrower Financial Ownership Information
Borrower Not Attempt Obtain Advance Knows Borrowers Credit Borrower Understands Agrees Ubs Bank Usa Demand
Business Calculation Appreciation
Capitalization Capitalization Adjustments
Capitalization Voting Rights Capitated Reimbursement Policies Adopted Create Disincentives Esas
Cash Equivalents Ccc
Centers Medicare Medicaid Services Cms Policies Constantly Changing Certain Fees
Certain Patent Matters Certain Relationships Related Transactions Director Independence
Certification Certifies
Change Control Change Vote After Submitting Proxy
Changes Internal Control Over Financial Reporting Changes Registrants Certifying Accountant
Check Writing Chemotherapy-induced Anemia
Choice Law Christi Van Heek
Christopher Dammann Clarification
Classes Directors Clevelands Dulieges Venteichers Agreements
Clinical Phase Related Expenses Clinical Trial Expense
Clinical Trial Expense Accruals Closing
Closing Certificate Cms Policies Constantly Changing Cannot Guarantee They Not
Co-promotion Co-sale Agreement
Code Business Conduct Ethics Code Ethics
Collaboration Guidelines Collaboration License Agreement
Collaboration Overview Collaboration Revenue
Collaboration Takeda Pharmaceutical Limited Collaborator Audit Right Bulk Hematide Facility
Collaborator Data Collaborator Know-how
Collaborator License Collaborator Patent
Collaborator Patents Other Joint Collaborator Regulatory Filings
Collaborator Rights Obligations Collaborators Performance
Collateral Account Ubs Financial Services Inc Collateral Grant Security Interest Set-off
Commercial Expenses Commercial Sale
Commercial Success Depends Attaining Significant Market Acceptance Hematide Commercial Supply Bulk Hematide
Commercialization Commercialization Licensed Territory
Commitment Development Plan Commitments Contingencies
Committees Board Directors Common Stock
Common Stock Options Reserved Shares Common Stock Purchase Agreement
Common Stock Purchase Agreement Compliance Certificate Common Stock Purchase Agreement Form Optional Amount Notice
Communications Companies Co-commercialize
Companies Decide Suspend Co-development Hematide Cia Focus Efforts Comparator Drugs
Comparison 2006 2005 Comparison 2007 2006
Comparison Cumulative Total Return Compensation
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Processes Procedures Compensation Committee Report
Compensation Program Objectives Competition
Competition Pharmaceutical Industry Intense Competitors Able Develop Market Competitive Market Review
Complete Agreement Compliance
Compliance 409a Compliance 409a Code
Compliance Certificate Compliance Law
Components Executive Compensation Program Comprehensive Income Loss
Comprehensive Loss Concentration Risk Uncertainties
Conditions Investors Obligations Closing Conditions Obligations Closing
Confidential Information Confidentiality
Conflict Conflicts
Consent Independent Registered Public Accounting Firm Consents Permits Waivers
Consideration Construction
Consultants Consultation Reporting Review
Contact Contacts
Continuing Effect Continuing Right Additional Product
Contractual Obligations Significant Commitments Control
Controls Procedures Cooperation
Cooperation Coordination Cooperation Obligation
Cooperation Prosecution Copy Annual Report Securities Exchange Form 10-k 2006
Copy Annual Report Securities Exchange Form 10-k 2007 Copy Annual Report Securities Exchange Form 10-k 2008
Corporate Action Constituting Grant Stock Awards Corporate Contact
Corporate Documents Corporate Existence Power
Corporate Seal Corporate Transaction
Cost Goods Sold Costs
Costs Expenses Counterparts
Counterparts Facsimile Delivery Covenants
Covenants Exercise Shares Creation Direct Financial Obligation Off-balance Sheet Arrangement
Credit Line Account Credit Line Agreement Demand Facility
Critical Accounting Policies Significant Judgments Estimates Cross-license Agreement
Cta Current Phase Clinical Trials
Current Report Current Therapy Limitations
Daniel Spiegelman Data Generated Affymax
Data Generated Behalf Collaborator Ddd
Death Optionholder Debarment
Decision Making Declaration Dividends
Defense Deferrals
Deferred Stock-based Compensation Definitions
Delaware Delays Omissions
Delegation Authority Delegation Officers
Deletion Certain Sections Departure Directors Certain Officers Election Appointment Compensatory
Dependence Parties Manufacture Supply Cause Delays Prevent Successfully Dependence Parties Manufacture Supply Products Cause Delays Prevent
Dependent Success Hematide Cannot Give Assurance Positive Clinical Dependent Success Hematide Cannot Give Assurance Receive Regulatory
Detail Detailing Develop Development
Development Development Budget
Development Commercialization Agreement Takeda Development Commercialization Agreements Takeda
Development Expenses Development Plan
Dialysis Ckd Anemia Difficult Costly Protect Proprietary Rights Not Able Ensure
Diligent Efforts Directors Executive Officers
Directors Executive Officers Corporate Governance Disability
Disability Optionholder Disclaimer
Disclosure Information Disclosure Inventions
Disputes Dissolution Liquidation
Distribution Expenses Dividend Equivalents
Dividend Policy Dividend Reserve
Documents Financial Statements Documents Incorporated Reference
Domestic Relations Orders Douglas Cole Phd
Duplicate Party Addendum Duties
Duties Chairman Board Directors Duties Chief Executive Officer
Duties Chief Financial Officer Duties President
Duties Secretary Duties Vice Presidents
Early Stage Development Limited Sources Revenue Current Recognition Eee
Effect Boards Decision Effect Termination Agreement
Effective Date Effective Date Plan
Effectiveness Effects Expiration
Election Directors Electronic Delivery
Eligibility Eligibility Specific Stock Awards
Eligible Stock Award Recipients Elizabeth Czerepak
Emea Employee Loans
Employee Stock Purchase Plan Employees
Employment Employment Agreement
Employment Other Service Rights Enforcement
English Language Governing Law Entire Agreement Amendment
Entire Agreement Nonassignability Parties Interest Entry Material Definitive Agreement
Environmental Compliance Enzon
Equity Compensation Plan Information Equity Grant Practices
Equity Incentive Plan Equity Incentive Plans
Establishment Credit Line Termination Estimates
European Union Evaluation Disclosure Controls Procedures
Evolve Primarily Involved Research Development Also Commercialization Encounter Exclusivity
Execution Corporate Instruments Execution Other Securities
Executive Committee Executive Compensation
Executive Compensation Actions Executive Officers Key Employees
Exemption Managements Report Internal Control Over Financial Reporting Exercise
Exercise Price Exhibits
Existing Agreements Existing Data
Expect Incur Substantial Costs Result Litigation Other Proceedings Expenses
Expenses Fees Extension Termination Date
Factors Uncertain Regulatory Climate Resulted Takedas Decision Fail Attract Keep Senior Management Key Scientific Personnel
Fail Maintain Existing Enter New Strategic Collaborations Reduce Fail Obtain Additional Financing Unable Complete Development Commercialization
Failure Delay Completing Clinical Trials Hematide Severely Harm Failure Delay Completing Clinical Trials Product Candidates Severely
Failure Delay Completing Clinical Trials Submission Nda Hematide Failure Maintain Effective Internal Controls Accordance 404 Sarbanes-oxley
Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Marketing Fair Value Financial Instruments
Fees Compensation Fff
Field Filing Restated Charter
Filings Regulatory Exclusivity Financial Definitions
Financial Guidance Financial Statement Exhibits
Financial Statements Financial Statements Exhibits
Find Out Results Voting Annual Meeting Finders Fee
Finished Manufacture Finished Product
Fixed Request Terms Optional Amount Fixing Record Dates
Force Majeure Foreign Exchange
Foreign Exchange Risk Foreign Governments Often Impose Strict Price Controls Adversely
Form 10-k Form 10-q
Form Execution Shares Form Letter Credit
Formation Role Formulation Technology
Forward-looking Statements Frequency Dosing
Further Actions Further Limitations Disposition
Future Agreements Future Data
Future Sales Common Stock Public Market Cause Price General
General Administrative Expenses General Provisions
General Release Not Extend Claims Creditor Know Suspect Good Clinical Practices
Good Laboratory Practices Good Laboratory Practices Glp
Good Manufacturing Practices Good Manufacturing Practices Gmp
Governing Law Government Regulation Product Approvals
Governmental Authority Governmental Consents
Grace Shin Grants Plan-based Awards 2007
Grants Plan-based Awards 2008 Gross-up Payment
Guidance Guiding Principles
Harmful Actions Headings
Held 2007 Hematide
Hematide Development Program Hematide Only Product Candidate Not Develop Other Candidates
Householding Proxy Materials However
Ices Gcp Impairment Long-lived Assets
Impairment Rights Implied Licenses
Important Disclosure Required Payments Incentive Stock Option 100000 Limitation
Incentive Stock Option Limit Income Taxes
Incur Significant Costs Complying Environmental Laws Regulations Failure Incur Significant Increased Costs Result Operating Public Management
Ind Indebtedness
Indemnification Affymax Indemnification Collaborator
Indemnification Limitation Liability Bank Securities Intermediary Indemnification Procedures
Indemnification Product Indemnification Takeda
Independence Board Directors Independent Contractors
Index Information
Infringement Affymax Joint Patents Licensed Territory Infringement Affymax Patents Joint Territory
Infringement Collaborator Patents Other Joint Licensed Territory Infringement Takeda Patents Other Joint Licensed Territory
Infringement Trademarks Parties Initial Awards
Initial Premises Work Letter Initial Press Release
Injunction Innotide-tissue Protective Peptides
Insurance Intangible Assets
Intellectual Property Intellectual Property Dispute
Interest Interest Income Expense Net
Interest Rate Risk Internal Expenses
Interpretation Investment Assurances
Investments Investors Rights Agreement
Involuntary Termination Involuntary Termination Following Change Control
Involuntary Termination Following Corporate Transaction Ipo Awards
Irst Amendment Collaboration License Agreement Issuance New Warrant
Issuance Shares Issuer Purchases Equity Securities
Japan Agreement Jeffrey Knapp
John Walker Joint Committee Members
Joint Committee Membership Joint Credit Line Account Agreement Suspension Cancellation
Joint Development Joint Owners Stock
Joint Patents Joint Steering Committee
Jsc Members Alliance Representatives Jsc Membership
Kathleen Laporte Kathleen Laporte Christi Van Heek Keith Leonard Continue
Kay Slocum Keith Leonard
Late Payments Launch Expenses
Laws Lead Product Candidate Hematide
Lee Douglas Legal Proceedings
Legends Level Efforts
Level Efforts Markets License Affymax Collaborator Technology
License Fee License Manufacturing Supply Agreement Nektar
License Royalty Revenue Licensed Territory
Licenses Collaborator Affymax Technology Limitation
Limitation Liability Limitations Effectiveness Controls
Limited License Affymax House Marks List Stockholders
Litigation Litigation Arbitration Chronology
Loans Officers Lost Certificates
Lost Stolen Mutilated Destroyed Warrant Managements Report Internal Control Over Financial Reporting
Mandatorily Redeemable Convertible Preferred Stock Manufacturing Costs
Manufacturing Development Manufacturing Development Expenses
Manufacturing Supply Market Common Stock
Market Opportunity Hematide Deteriorate Significantly After Entry Biosimilars Market Opportunity Hematide Deteriorate Significantly After Existing Repo
Market Price Common Stock Been Highly Volatile Likely Market Price Common Stock Highly Volatile Not Able
Market Registrants Common Equity Related Stockholder Matters Issuer Marketable Securities
Marketing Authorization Application Marketing Authorization Application Maa
Marketing Sales Material Agreements
Material Weakness Internal Control Over Financial Reporting Material Weaknesses Internal Control Over Financial Reporting
Medical Science Liaison Expenses Medicare Reimbursement Policies New Bundled Payment System Create
Meeting Agendas Meetings
Meetings Board Directors Meetings Electronic Communications Equipment
Methods Notice Miranda Avenue Palo Alto 94304
Miranda Avenue Palo Alto 94304 650 812-8700 Miranda Avenue Palo Alto California 94304
Morris Agreement Must-take Work Letter
Mutual Representations Warranties Name Borrower
Nda Negative Covenant
Nektar Nektar Agreement
Net Exercise Net Loss Per Common Share
Net Operating Losses Tax Credit Carryforwards Net Sales
Nicholas Galakatos Phd Nominating Corporate Governance Committee
Non-director Executive Officers Key Employees Non-exclusivity Rights
Non-exempt Employees Nonemployee Stock-based Compensation
Noninterference Not Able Recover Value Ars Settlement Ubs
Not Applicable Notice
Notice Annual Meeting Stockholders Held 2009 Notice Co-signer Traduccion Ingles Requiere Por Ley
Notice Directors Notice Exercise
Notice Meetings Notice Person Communication Unlawful
Notice Special Meetings Notice Stockholders
Notice Stockholders Sharing Address Notices
Notices Etc Notices Record Date Certain Other Events
Notification Now Therefore
Number Term Office Obligation Notify
Off-balance Sheet Arrangements Offering
Officers Designated Oncology Indications
Operation Business Operations Adversely Impacted Exposure Risks Related Foreign Currency
Opinion Counsel Certificate Option Exercises Stock Vested 2007
Option Exercises Stock Vested 2008 Option Provisions
Orange Book Listing Compendial Organization
Organization Good Standing Qualification Other
Other Committees Other Events
Other Income Expense Net Other Information
Other Matters Other Officers Employees Agents
Other Offices Other Remedies
Other Remedies Affymax Breach Other Representations Warranties
Other Stock Awards Other Transactions
Outside Activities Employment Outstanding Equity Awards End
Overview Ownership
Ownership Inventions Palo Alto 94304
Palo Alto Calif Palo Alto Calif 2007
Palo Alto Calif 2008 Palo Alto Calif 2009
Palo Alto Calif Deceber 2007 Palo Alto California 94304
Parallel Programs Part
Partial Termination Parties Patent Rights
Party Party Intellectual Property
Party Licenses Party Royalties
Patent Applications Filed After Agreement Patent House Trademark Matters Licensed Territory
Patent Marking Patent Matters Licensed Territory
Patent Oppositions Other Proceedings Patent Term Extension
Patent Term Extensions Licensed Territory Patent Trademark Dispute Resolution
Patents Patents Japanese Licensee
Paul Cleveland Paul Cleveland Executive Vice President Corporate Development Chief
Paying Proxy Solicitation Payment
Payment Stock Awards Lieu Exercise Payment Tax
Payment Taxes Expenses Payments
Pde Peptide
Peptide Structure Percent Stockholders
Performance Affiliates Performance Compensation Process
Performance Diligence Performance Graph
Performance Obligations Performance Stock Awards
Permits Phase Clinical Trial
Phase Development Plans Phase Iiib Clinical Trial
Place Meetings Plan Remediation Material Weakness
Plan Remediation Material Weaknesses Plan Term
Please Fold Along Perforation Detach Return Bottom Portion Portion Investments Consists Auction Rate Securities Ars Market
Post-rd Agreement Development Activities Potential Hematide Advantages
Powers Powers Board
Pre-approval Policies Procedures Pre-dialysis Ckd Anemia
Pre-marketing Expenses Preclinical Clinical Supply Bulk Hematide
Preclinical Study Clinical Trial Accruals Preclinical Toxicology Studies
Preferred Stock Preparation
Prepayments Breakage Charges Pricing Approval
Pricing Approvals Pricing Approvals Licensed Territory
Pricing Product Licensed Territory Primary Position Detail
Principal Accountant Fees Services Principal Accounting Fees Services
Principal Stockholders Management Own Significant Percentage Stock Able Principles Product Development
Proceeds Proceeds Sale Registered Securities
Product Product Candidate Hematide
Product Candidates Other Hematide Early Stage Research Unable Product Complaint
Product Infringement Collaborator Patents Other Joint Affymax Territory Product Labeling
Product Labeling Promotional Materials Product Liability Lawsuits Brought Against Incur Substantial Liabilities
Product Profit Product Subcommittee
Product Trademark Profit Equalization Payment
Project Coordinator Project Coordinators
Promotional Materials Properties
Property Equipment Property Equipment Net
Proposal Proposals Board Directors Recommends Vote Nominees Director Listed
Proprietary Information Agreement Proprietary Information Obligations
Provided However Provision Benefit Income Taxes
Provision Income Taxes Proxy Solicited Board Directors
Publications Publicity Terms Agreement
Purchase Entirely Own Account Purchasers
Pure Red Cell Aplasia Purpose
Quality Agreement Quantitative Qualitative Disclosure Market Risks
Quarterly Financial Data Quorum
Quorum Voting Rate Patented Products
Ratification Selection Independent Registered Public Accounting Firm Reagent
Recalls Voluntary Withdrawals Receiving Materials
Recent Accounting Pronouncements Recent Sales Unregistered Securities
Recitals Reclassifications
Reclassifications Adjustments Records Audits
Records Reports Information Referred Joint Committee
Registered Office Registered Stockholders
Registration Exclusive License Regular Meetings
Regulatory Regulatory Approval Process Expensive Time Consuming Uncertain Prevent
Regulatory Approvals Regulatory Authority
Regulatory Authority Communications Received Party Regulatory Costs
Regulatory Exclusivity Regulatory Expenses
Regulatory Inspection Audit Regulatory Materials
Regulatory Materials Studies Reimbursement Not Available Hematide Materially Diminish Sales Ability
Reimbursement Not Available Product Candidates Diminish Sales Affect Reimbursement Procedures
Rejection Failure Agree Related Party Transactions
Related-person Transactions Policy Procedures Release
Release Agreement Reliance
Reliance Others Rely Parties Conduct Pre-clinical Studies Clinical Trials Hematide
Rely Parties Conduct Preclinical Clinical Trials Hematide They Rely Parties Conduct Preclinical Clinical Trials Product Candidates
Remaining Inventories Remaining Terms
Remediation Prior Material Weakness Remediation Prior Material Weaknesses
Remedies Remedies Cumulative
Removal Renal Indications
Replacement Product Candidate Replacement Products
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Reports Representations Warranties
Representations Warranties Covenants Loan Parties Representations Warranties Investor
Representations Warranties Investors Representations Warranties True
Representations Warranties True Performance Obligations Research
Research Development Agreement Research Development Expenses
Research Pipeline Reservation Conversion Shares
Resignation Resignations
Restricted Cash Restricted Stock Awards
Restricted Stock Unit Awards Restriction Licensing Compounds
Restrictions Transfer Results Operations Financial Condition
Retirement Savings Plan Revenue
Revenue Recognition Reverse Stock Split
Reversion Shares Share Reserve Revised 2008 Financial Guidance
Revisions Previously Reported Financial Information Right Negotiation Backup Compounds
Right Refusal Backup Product Developed Field Right Work
Rights Bankruptcy Rights Reference Regulatory Materials
Rincipal Ccountant Ees Ervices Risk Securities Class Action Litigation
Risks Related Industry Risks Related Ownership Common Stock
Robert Naso Phd Robert Venteicher
Robert Venteicher Phd Senior Vice President Technical Operations Role Compensation Committee
Roles Parties Row Development
Royalty Payments Reports Royalty Rate
Royalty Rate Step Down Royalty Rate Step Down Term Obligation
Royalty Territory Royalty Territory Information Sharing
Royalty Territory Reports Rule 16b-3 Compliance
Rules Construction Sale Issuance Series Preferred Stock
Sales Call Sales Distribution
Sales Force Training Commercialization Sales Milestone Payments
Sales Representative Saving Clause
Schedule 102 Schedule 14a
Schedule Ubs Bank Usa Credit Line Agreement Schedules
Secondary Position Detail Secretarys Certificate
Securities Act Securities Law Compliance
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management Related Stockholder
Segment Information Selling Restrictions
Series Preferred Stock Purchase Agreement Settlement
Settlement Payment Severability
Share Reserve Sharing Expenses Product Profit
Sho Signature Page Follows
Signatures Significant Equity Transactions
Some Provisions Charter Documents Delaware Law Anti-takeover Effects Source Shares
Special Meetings Standards Using Affymax House Marks
Steven Love Steven Love Individual
Steven Love Vice President Finance Stock Appreciation Rights
Stock Awards Assumed Stock Awards Held Current Participants
Stock Awards Held Former Participants Stock Option Activity
Stock Option Issuance Plan Stock Purchase Agreement
Stock-based Compensation Stock-based Compensation After Adoption Sfas 123
Stock-based Compensation Before Adoption Sfas 123 Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholder Rights Strict Construction Headings
Strike Price Structure
Subcommittees Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Subsidiaries Successor Continuation Prior Plan
Successors Assigns Sufficiency License Grants
Sufficiency License Grants Affymax Patents Suit Action Proceeding Arising Out Related Agreement Transactions
Summary Compensation Table 2007 2006 Summary Non-employee Director Compensation Program
Supply Supply Bulk Api Finished Product Affymax
Supply Bulk Hematide Affymax Survival
Survival Representations Warranties Survival Rights
Takeda Takeda Agreements
Takeda Know-how Takeda License
Takeda Patent Takeda Patents Other Joint
Tax Residence Certificate Ted Love
Teleconference Webcast Details Term
Termination Breach Termination Cause
Termination Change Control Termination Continuous Service
Termination Employment Termination Good Reason
Termination Licenses Termination Participants Continuous Service
Termination Without Cause Terms Advances
Territory Tertiary Position Detail
Third-party Intellectual Property Third-party Patent Rights
Time Launch Product Title Assets
Title Properties Assets Liens Etc Tracy Dunn Phd
Transactions Affiliates Transfer Warrant
Transferability Transferability Options
Transfers Transition Assistance
Treat Anemia Chronic Renal Failure Ubs Loan
Unable Either Create Sales Marketing Distribution Capabilities Enter Unable Successfully Assess Effectiveness Internal Control Over Financial
Unregistered Sales Equity Securities Updates Development Plan Budget
Vacancies Valid Claim
Valid Issuance Series Preferred Stock Valuation Investments
Vesting Vesting Options Generally
Voluntary Mutual Termination Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Voting Agreement Voting Rights
Voting Securities Owned Corporation Waiver
Waiver Notice Warrants
What Broker Non-votes What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting Whereas
Withdrawal Takeda Withholding Obligations
Witness Whereof Yakka
Yen 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki